Expertise in
21
conditions

Masaaki Mori

Tokyo, JP 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
21
conditions
Tokyo, JP 

Overview

Masaaki Mori practices practicing medicine in Tokyo, Japan.

Mr. Mori is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Juvenile Idiopathic Arthritis (JIA), Respiratory Syncytial Virus (RSV) Infection, Kawasaki Disease, and Arthritis.

He is actively involved in clinical research, co-authoring 217 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Tokyo, Japan
Other Locations
Japan
St. Marianna University School Of Medicine, Kawasaki, Japan
Yushima, 1138510, Japan
Yokohama, Japan
Toyota, Japan
St. Marianna University Hospital
Kanagawa, Japan
Kanazawa, Japan
Keio, Japan
Bunkyo, Japan
Nagoya, Japan
Shinjuku, 1608582, Japan
Osaka, Japan
Yokosuka, Japan
Matsumoto, Japan
Fujisawa, Japan
Kagoshima, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: August 24, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Combination product
Study Drug: Belimumab
Study Phase: Phase 2
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 3 Less Clinical Trials

217 Total Publications

Clinical Characteristics of Enthesitis-Related Arthritis and Outcomes of Treatment with Salazosulfapyridine.
Clinical Characteristics of Enthesitis-Related Arthritis and Outcomes of Treatment with Salazosulfapyridine.
Journal: Modern rheumatology
Published: April 07, 2026

Frequently Asked Questions about Masaaki Mori

Is Masaaki Mori a top-rated expert for Juvenile Idiopathic Arthritis (JIA)?

MediFind is an objective health platform that identifies experts based on real-world data. Masaaki Mori is classified as an Distinguished expert for Juvenile Idiopathic Arthritis (JIA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Masaaki Mori participate in research or clinical trials?

Yes. Masaaki Mori has published 217 articles and abstracts on conditions like Juvenile Idiopathic Arthritis (JIA). You can view a list of Masaaki Mori's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mori's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 72 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile